Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions

Current Heart Failure Reports

Volumn 14, Issue 2, 2017, Pages 59-70

  Lund, Lars H ^a,b   Oldgren, Jonas ^c   James, Stefan ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cost; Heart failure; Pragmatic clinical trial; Prospective randomized clinical trial; Registry; Registry based pragmatic trial; Registry based prospective randomized clinical trial

Indexed keywords

DABIGATRAN; NESIRITIDE; SACUBITRIL PLUS VALSARTAN; SPIRONOLACTONE;

ATRIAL FIBRILLATION; CLINICAL OUTCOME; DISEASE REGISTRY; DRUG COST; DRUG EFFICACY; ELECTRONIC HEALTH RECORD; HEART FAILURE; HOSPITALIZATION; HUMAN; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VENTRICULAR ASSIST DEVICE; CHRONIC DISEASE; ETHICS; FEASIBILITY STUDY; LEGISLATION AND JURISPRUDENCE; PATIENT SELECTION; PROSPECTIVE STUDY; REGISTER;

CHRONIC DISEASE; FEASIBILITY STUDIES; HEART FAILURE; HUMANS; PATIENT SELECTION; PRAGMATIC CLINICAL TRIALS AS TOPIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES;

EID: 85014030240     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-017-0325-0     Document Type: Review

References (119)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014 Jan 21;129(3):e28-e292
2. • Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123–33. Contemporary real-world data on the burden of HF
3. Lund LH, Benson L, Dahlstrom U, Edner M, Friberg L. Association between use of beta-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA. 2014;312(19):2008–18.
4. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606–19.
5. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.
6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810–52.
7. Thorvaldsen T, Benson L, Dahlstrom U, Edner M, Lund LH. Use of evidence-based therapy and survival in heart failure in Sweden 2003–2012. Eur J Heart Fail. 2016;18(5):503–11.
8. Lund LH, Benson L, Stahlberg M, Braunschweig F, Edner M, Dahlstrom U, et al. Age, prognostic impact of QRS prolongation and left bundle branch block, and utilization of cardiac resynchronization therapy: findings from 14 713 patients in the Swedish Heart Failure Registry. Eur J Heart Fail. 2014;16(10):1073–81.
9. Thorvaldsen T, Benson L, Stahlberg M, Dahlstrom U, Edner M, Lund LH. Triage of patients with moderate to severe heart failure: who should be referred to a heart failure center? J Am Coll Cardiol. 2014;63(7):661–71.
10. Lund LH, Hauptman PJ. Unmet needs and prioritization in heart failure. J Card Fail. 2016;22(8):587–8.
11. Lund LH, Matthews J, Aaronson K. Patient selection for left ventricular assist devices. Eur J Heart Fail. 2010;12(5):516–20.
12. Edner M, Benson L, Dahlstrom U, Lund LH. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. Eur Heart J. 2015;11.
13. Lund LH, Donal E, Oger E, Hage C, Persson H, Haugen-Lofman I, et al. Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014;16(9):992–1001.
14. • Lam CS, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). Eur J Heart Fail. 2014;16(10):1049–55. A seminal paper addressing the unmet needs in HF with mid-range ejection fraction
15. Vaduganathan M, Michel A, Hall K, Mulligan C, Nodari S, Shah SJ, et al. Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. Eur J Heart Fail. 2016;18(1):54–65.
16. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9.
17. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation. 2015;131(1):34–42.
18. Lund LH, Benson L, Dahlstrom U, Edner M. Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA. 2012;308(20):2108–17.
19. Rogers JK, Pocock SJ, McMurray JJ, Granger CB, Michelson EL, Ostergren J, et al. Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. Eur J Heart Fail. 2014;16(1):33–40.
20. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.
21. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.
22. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.
23. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.
24. •• Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart failure. 2014;2(2):97–112. Proceedings from a meeting between academia, industry and regulatory agencies, highlighting the challenges in developing therapy for HFpEF
25. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233–70.
26. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2015;9(3):e002744
27. Lund LH. Heart failure with “mid-range” ejection fraction—new opportunities. J Card Fail. 2016 ;25.
28. Collins S, Storrow AB, Albert NM, Butler J, Ezekowitz J, Felker GM, et al. Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the Society for Academic Emergency Medicine/Heart Failure Society of America acute Heart Failure Working Group. J Card Fail. 2015;21(1):27–43.
29. Butler J, Gheorghiade M, Kelkar A, Fonarow GC, Anker S, Greene SJ, et al. In-hospital worsening heart failure. Eur J Heart Fail. 2015;17(11):1104–13.
30. Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015;17(6):544–58.
31. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med. 2006;119(12 Suppl 1):S3–S10.
32. • Bothwell LE, Greene JA, Podolsky SH, Jones DS. Assessing the gold standard—lessons from the history of RCTs. N Engl J Med. 2016;374(22):2175-81. An overview of the history of RCTs
33. Ferriman A. BMJ readers choose the “sanitary revolution” as greatest medical advance since 1840. BMJ. 2007;334:111.
34. Antman EM, Harrington RA. Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being. JAMA. 2012;308(17):1743–4.
35. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010. JAMA. 2012;307(17):1838–47.
36. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med. 2015;372(11):1031–9.
37. Gordon D, Taddei-Peters W, Mascette A, Antman M, Kaufmann PG, Lauer MS. Publication of trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2013;369(20):1926–34.
38. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith Jr SC. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301(8):831–41.
39. James S, Frobert O, Lagerqvist B. Cardiovascular registries: a novel platform for randomised clinical trials. Heart. 2012;98(18):1329–31.
40. James S, Rao SV, Granger CB. Registry-based randomized clinical trials—a new clinical trial paradigm. Nat Rev Cardiol. 2015;12(5):312–6
41. Lauer MS, D’Agostino RB, Sr. The randomized registry trial—the next disruptive technology in clinical research? N Engl J Med. 2013;369(17):1579–81
42. • Bhatt DL, Drozda Jr JP, Shahian DM, Chan PS, Fonarow GC, Heidenreich PA, et al. ACC/AHA/STS Statement on the Future of Registries and the Performance Measurement Enterprise: a Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and The Society of Thoracic Surgeons. J Am Coll Cardiol. 2015;66(20):2230–45. A statement of the future role of registries for quality and performance reporting
43. • Lund LH, Carrero, J.J., Farahmand, B., Henriksson, K.M., Jonsson, Å., Jernberg, T., Dahlström, U. Association between enrolment in a heart failure quality registry and subsequent mortality—a nationwide cohort study. Eur J Heart Fail. 2017;in press. The first study establishing a direct assocation between enrolment in a HF quality registry and not only improved quality of care but also reduced mortality
44. Stehlik J, Bavaria JE, Bax J, Cronenwett JL, Edwards LB, Fairman RM, et al. Heart, lung, and vascular registries: evolving goals, successful approaches, and ongoing innovation. J Heart Lung Transplant. 2016;35(10):1149–57.
45. Lund LH, Stehlik J. Risk scores and biomarkers in heart failure: a journey to predictive accuracy and clinical utility. J Heart Lung Transplant. 2016;35(6):711–3.
46. Sartipy U, Dahlstrom U, Edner M, Lund LH. Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish Heart Failure Registry. Eur J Heart Fail. 2014;16(2):173–9.
47. Peterson PN, Chan PS, Spertus JA, Tang F, Jones PG, Ezekowitz JA, et al. Practice-level variation in use of recommended medications among outpatients with heart failure: insights from the NCDR PINNACLE program. Circ Heart Fail. 2013;6(6):1132–8.
48. Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15(10):1173–84.
49. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808–17.
50. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167(14):1493–502.
51. Fonarow GC, Albert NM, Curtis AB, Gheorghiade M, Liu Y, Mehra MR, et al. Incremental reduction in risk of death associated with use of guideline-recommended therapies in patients with heart failure: a nested case–control analysis of IMPROVE HF. J Am Heart Assoc. 2012;1(1):16–26.
52. Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation. 2010;122(6):585–96.
53. Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med. 2005;165(13):1469–77.
54. Heidenreich PA, Hernandez AF, Yancy CW, Liang L, Peterson ED, Fonarow GC. Get With The Guidelines program participation, process of care, and outcome for Medicare patients hospitalized with heart failure. Circ Cardiovasc Qual Outcomes. 2012;5(1):37–43.
55. Eapen ZJ, Fonarow GC, Dai D, O’Brien SM, Schwamm LH, Cannon CP, et al. Comparison of composite measure methodologies for rewarding quality of care: an analysis from the American Heart Association’s Get With The Guidelines program. Circ Cardiovasc Qual Outcomes. 2011;4(6):610–8.
56. Crespo-Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18(6):613–25.
57. Gijsberts CM, Benson L, Dahlstrom U, Sim D, Yeo DP, Ong HY, et al. Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure. Heart. 2016;102(18):1464–71
58. Bank IE, Gijsberts CM, Teng TK, Benson L, Sim D, Yeo PS, et al. Prevalence and clinical significance of diabetes in Asian versus White patients with heart failure. JACC Heart failure. 2016;S2213–1779(16)30501–7.
59. Jonsson A, Edner M, Alehagen U, Dahlström U. Heart failure registry: a valuable tool for improving the management of patients with heart failure. Eur J Heart Fail. 2010;12(1):25–31.
60. Braunschweig F, Linde C, Benson L, Stahlberg M, Dahlstrom U, Lund LH. New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resychronization therapy. Eur J Heart Fail. 2016;23.
61. Linde C, Stahlberg M, Benson L, Braunschweig F, Edner M, Dahlstrom U, et al. Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. Europace. 2014;27.
62. Thorvaldsen T, Benson L, Hagerman I, Dahlstrom U, Edner M, Lund LH. Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden. Int J Cardiol. 2014;175(1):55–61.
63. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med. 2000;342(25):1907–9.
64. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887–92.
65. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–86.
66. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group Lancet. 2000;355(9215):1575–81.
67. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624–32.
68. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
69. • Jones WS, Roe MT, Antman EM, Pletcher MJ, Harrington RA, Rothman RL, et al. The changing landscape of randomized clinical trials in cardiovascular disease. J Am Coll Cardiol. 2016;68(17):1898–907. A review of the problems with conventional RCTs and opportunities with registry-based and pragmatic trials
70. Califf RM, Sanderson I, Miranda ML. The future of cardiovascular clinical research: informatics, clinical investigators, and community engagement. JAMA. 2012;308(17):1747–8.
71. Califf RM, Platt R. Embedding cardiovascular research into practice. JAMA. 2013;310(19):2037–8.
72. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62(5):464–75.
73. • Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454–63. A contemporary review of pragmatic trials
74. Fiore LD, Lavori PW. Integrating randomized comparative effectiveness research with patient care. N Engl J Med. 2016;374(22):2152–8.
75. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1(8478):397–402.
76. Collins R, Peto R, Sleight P. Significant reduction in mortality with streptokinase given 7–24 hours after pain onset. Lancet. 1988;2(8621):1187–8.
77. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283(15):1967–75.
78. Rao SV, Hess CN, Barham B, Aberle LH, Anstrom KJ, Patel TB, et al. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. JACC Cardiovascular interventions. 2014;7(8):857–67.
79. • Hernandez AF, Fleurence RL, Rothman RL. The ADAPTABLE Trial and PCORnet: shining light on a new research paradigm. Ann Intern Med. 2015;163(8):635–6. A notable pragmatic trial in the US
80. Vaillant-Roussel H, Laporte C, Pereira B, De Rosa M, Eschalier B, Vorilhon C, et al. Impact of patient education on chronic heart failure in primary care (ETIC): a cluster randomised trial. BMC Fam Pract. 2016;17:80.
81. Clark AL, Johnson M, Fairhurst C, Torgerson D, Cockayne S, Rodgers S, et al. Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure. Health Technol Assess. 2015;19(75):1–120.
82. Stewart S, Chan YK, Wong C, Jennings G, Scuffham P, Esterman A, et al. Impact of a nurse-led home and clinic-based secondary prevention programme to prevent progressive cardiac dysfunction in high-risk individuals: the Nurse-led Intervention for Less Chronic Heart Failure (NIL-CHF) randomized controlled study. Eur J Heart Fail. 2015;17(6):620–30.
83. O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32–43.
84. Anell A. The public-private pendulum—patient choice and equity in sweden. N Engl J Med. 2015;372(1):1–4.
85. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–67.
86. Ingelsson E, Arnlov J, Sundstrom J, Lind L. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail. 2005;7(5):787–91.
87. Frobert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med. 2013;369(17):1587–97.
88. Lagerqvist B, Frobert O, Olivecrona GK, Gudnason T, Maeng M, Alstrom P, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med. 2014;371(12):1111–20.
89. •• Mentz RJ, Hernandez AF, Berdan LG, Rorick T, O’Brien EC, Ibarra JC, et al. Good clinical practice guidance and pragmatic clinical trials: balancing the best of both worlds. Circulation. 2016;133(9):872–80. A discussion of the role of GCP in the the conduct of pragmatic trials
90. Califf RM, Harrington RA. American industry and the U.S. Cardiovascular Clinical Research Enterprise an appropriate analogy? J Am Coll Cardiol. 2011;58(7):677–80.
91. •• Butler J, Tahhan AS, Georgiopoulou VV, Kelkar A, Lee M, Khan B, et al. Trends in characteristics of cardiovascular clinical trials 2001–2012. Am Heart J. 2015;170(2):263–72. A contemporary review of pragmatic trials
92. • Jackson N, Atar D, Borentain M, Breithardt G, van Eickels M, Endres M, et al. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. Eur Heart J. 2016;37(9):747–54.A European proposal on strategies to improve development of new CV therapy
93. • Getz KA, Stergiopoulos S, Marlborough M, Whitehill J, Curran M, Kaitin KI. Quantifying the magnitude and cost of collecting extraneous protocol data. Am J Ther. 2015;22(2):117–24. An analysis specifically of the role of extraneous data in trials
94. •• Eapen ZJ, Lauer MS, Temple RJ. The imperative of overcoming barriers to the conduct of large, simple trials. JAMA. 2014;311(14):1397–8. A comprehensive review of the complexity of conventional trials
95. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97.
96. • Sugarman J, Califf RM. Ethics and regulatory complexities for pragmatic clinical trials. JAMA. 2014;311(23):2381–2. A review of ethics an regulatory aspects of pragmatic trials
97. Kim SY, Miller FG. Informed consent for pragmatic trials—the integrated consent model. N Engl J Med. 2014;370(8):769–72
98. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088–97.
99. Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. Lancet. 2004;364(9442):1321–8.
100. Gordon D. Randomized registry trial: TASTE of things to come. American College of Cardiology Scientific Sessions. 2015.
101. •• Butler J, Fonarow GC, O’Connor C, Adams K, Bonow RO, Cody RJ, et al. Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. Am Heart J. 2015;169(3):305–14. Perspectives and recommendations from a meeting between clinicians, researchers, sponsors, and regulators on how to improve clinical trials
102. Kim ES, Carrigan TP, Menon V. International participation in cardiovascular randomized controlled trials sponsored by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2011;58(7):671–6.
103. Rossignol P, Zannad F. Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west. Circulation. 2015;131(1):7–10.
104. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.
105. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001;345(20):1435–43.
106. Slaughter MSRJG, Milano CA, Russel SD, Conte JV, Feldman D, Sun B, et al. Advanced heart failure treated with continous-flow left ventricular assist device. N Engl J Med. 2009;361(23):2241–51.
107. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20(8):637–48.
108. Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297(11):1233–40.
109. Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011;171(6):550–6.
110. Butler J, Subacius H, Vaduganathan M, Fonarow GC, Ambrosy AP, Konstam MA, et al. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J Am Coll Cardiol. 2013;61(5):571–9.
111. Cooper LB, Hammill BG, Peterson ED, Pitt B, Maciejewski ML, Curtis LH, et al. Consistency of laboratory monitoring during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. JAMA. 2015;314(18):1973–5.
112. Lund LH, Svennblad B, Melhus H, Hallberg P, Dahlstrom U, Edner M. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study. Circ Heart Fail. 2013;5.
113. Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012;308(20):2097–107.
114. Herper M. The cost of creating a new drug now $5 billion, pushing big pharma to change 2013 [cited 2017 02-jan-2017]. Available from: http://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/#124410cf6bfc.
115. Berggren R, Moller M, Moss R, Poda P, Smietana K. Outlook for the next 5 years in drug innovation. Nat Rev Drug Discov. 2012;11(6):435–6.
116. Extraneous data collected in clinical trials cost drug developers $4 billion to $6 billion annually 2012 [cited 2017 03-jan-2017]. Available from: http://csdd.tufts.edu/files/uploads/11_-_nov_6,_2012_-_extraneous_data.pdf
117. Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134(13):e282–93.
118. Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, et al. Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016;1(6):666–72.
119. Nathan DG, Varmus HE. The National Institutes of Health and clinical research: a progress report. Nat Med. 2000;6(11):1201–4.